Subscribe To
iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing
– Immuno-oncology candidate discovered using iBio’s AI epitope steering platform – – Expands Treg depletion franchise beyond IBIO-101 – BRYAN, Texas, March 31, 2023 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the progression of its anti-CCR8 antibody immuno-oncology program into preclinical in vivo […] The post iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing appeared fi...
Read More
Posted: Mar 31 2023, 12:10
Author Name: forextv
Views: 082113